This statistic shows the likelihood of approval from Phase I for new drugs in the U.S., within the period from January 1, 2011, to November 30, 2020, by disease area. It was found that the likelihood of approval from Phase I of drug development was highest for drugs in hematology.
Likelihood of approval from phase I for new drugs in select disease areas in the U.S. between 2011 and 2020
Only company-sponsored, FDA registration-enabling development
programs were included in this analysis. Investigator-sponsored studies and combinations with other
investigational drugs were excluded.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Biotechnology Innovation Organization, & Pharma Intelligence, & QLS Advisors. (February 26, 2021). Likelihood of approval from phase I for new drugs in select disease areas in the U.S. between 2011 and 2020 [Graph]. In Statista. Retrieved December 21, 2024, from https://www.statista.com/statistics/597676/drug-development-phase-one-to-approval-probability-of-success/
Biotechnology Innovation Organization, und Pharma Intelligence, und QLS Advisors. "Likelihood of approval from phase I for new drugs in select disease areas in the U.S. between 2011 and 2020." Chart. February 26, 2021. Statista. Accessed December 21, 2024. https://www.statista.com/statistics/597676/drug-development-phase-one-to-approval-probability-of-success/
Biotechnology Innovation Organization, Pharma Intelligence, QLS Advisors. (2021). Likelihood of approval from phase I for new drugs in select disease areas in the U.S. between 2011 and 2020. Statista. Statista Inc.. Accessed: December 21, 2024. https://www.statista.com/statistics/597676/drug-development-phase-one-to-approval-probability-of-success/
Biotechnology Innovation Organization, and Pharma Intelligence, and QLS Advisors. "Likelihood of Approval from Phase I for New Drugs in Select Disease Areas in The U.S. between 2011 and 2020." Statista, Statista Inc., 26 Feb 2021, https://www.statista.com/statistics/597676/drug-development-phase-one-to-approval-probability-of-success/
Biotechnology Innovation Organization & Pharma Intelligence & QLS Advisors, Likelihood of approval from phase I for new drugs in select disease areas in the U.S. between 2011 and 2020 Statista, https://www.statista.com/statistics/597676/drug-development-phase-one-to-approval-probability-of-success/ (last visited December 21, 2024)
Likelihood of approval from phase I for new drugs in select disease areas in the U.S. between 2011 and 2020 [Graph], Biotechnology Innovation Organization, & Pharma Intelligence, & QLS Advisors, February 26, 2021. [Online]. Available: https://www.statista.com/statistics/597676/drug-development-phase-one-to-approval-probability-of-success/
